Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Koenigsmann

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Annals of Hematology|October 4, 2023
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trialSteffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
European Journal of Haematology|July 7, 2025
Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical RoutineSteffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
Optics Express|September 23, 2025
High-speed silicon photonics ring-resonator modulators for optical-amplification-free linksArmands Ostrovskis, Toms Salgals, Michael Koenigsmann, et al.
British Journal of Cancer|October 14, 2025
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)Manfred P Lutz, Nikolaus Ansorge, Gleb Barmashenko, et al.
European Journal of Haematology|May 2, 2024
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registryNadine Kutsch, Adam Giza, Sandra Robrecht, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 9, 2017
Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell TransplantationNicolaus Kröger, Victoria Panagiota, Anita Badbaran, et al.
JAMA Oncology|April 28, 2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 TrialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
The Lancet. Oncology|October 26, 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, et al.
International Journal of Cancer|October 10, 2020
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registrySalah-Eddin Al-Batran, Ralf-Dieter Hofheinz, Alexander Reichart, et al.
Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Annals of Hematology|October 4, 2023
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trialSteffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
European Journal of Haematology|July 7, 2025
Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical RoutineSteffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
Optics Express|September 23, 2025
High-speed silicon photonics ring-resonator modulators for optical-amplification-free linksArmands Ostrovskis, Toms Salgals, Michael Koenigsmann, et al.
British Journal of Cancer|October 14, 2025
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)Manfred P Lutz, Nikolaus Ansorge, Gleb Barmashenko, et al.
European Journal of Haematology|May 2, 2024
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registryNadine Kutsch, Adam Giza, Sandra Robrecht, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 9, 2017
Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell TransplantationNicolaus Kröger, Victoria Panagiota, Anita Badbaran, et al.
JAMA Oncology|April 28, 2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 TrialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
The Lancet. Oncology|October 26, 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, et al.
International Journal of Cancer|October 10, 2020
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registrySalah-Eddin Al-Batran, Ralf-Dieter Hofheinz, Alexander Reichart, et al.
Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
Pageof 3